Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus SBRT in second- and third-line metastatic renal cell carcinoma
2016-003032-20Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in metastatic renal cell carcinoma (mRCC), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Objective response rate. Started Jan 2021; status: completed.
02
Drugs
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2016-003032-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003032-20.